Name | Number of supported studies | Average coverage | |
---|---|---|---|
type I pneumocyte | 10 studies | 36% ± 15% | |
endothelial cell | 10 studies | 24% ± 13% | |
pericyte | 9 studies | 28% ± 14% | |
ciliated cell | 6 studies | 28% ± 9% | |
basal cell | 6 studies | 26% ± 9% | |
epithelial cell | 5 studies | 39% ± 13% | |
secretory cell | 4 studies | 28% ± 11% | |
endothelial cell of artery | 4 studies | 29% ± 19% | |
club cell | 4 studies | 23% ± 7% | |
mesothelial cell | 3 studies | 31% ± 18% | |
kidney loop of Henle epithelial cell | 3 studies | 22% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 26% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4880.00 | 1440 / 1445 | 99% | 186.80 | 182 / 183 |
kidney | 100% | 19392.93 | 89 / 89 | 96% | 146.39 | 863 / 901 |
lung | 100% | 9053.91 | 577 / 578 | 96% | 120.72 | 1106 / 1155 |
pancreas | 100% | 7443.91 | 328 / 328 | 96% | 122.52 | 170 / 178 |
thymus | 100% | 16098.52 | 653 / 653 | 95% | 131.88 | 576 / 605 |
bladder | 100% | 6458.81 | 21 / 21 | 95% | 112.59 | 479 / 504 |
intestine | 100% | 4340.04 | 966 / 966 | 95% | 75.88 | 499 / 527 |
skin | 100% | 6237.49 | 1809 / 1809 | 94% | 102.61 | 444 / 472 |
uterus | 100% | 4755.76 | 170 / 170 | 93% | 114.70 | 427 / 459 |
stomach | 100% | 4645.34 | 359 / 359 | 93% | 84.94 | 266 / 286 |
breast | 99% | 6903.02 | 455 / 459 | 93% | 80.09 | 1044 / 1118 |
prostate | 100% | 6830.17 | 245 / 245 | 92% | 54.35 | 461 / 502 |
ovary | 91% | 2189.68 | 163 / 180 | 100% | 199.25 | 428 / 430 |
brain | 92% | 4985.47 | 2433 / 2642 | 95% | 71.08 | 671 / 705 |
liver | 100% | 3612.33 | 226 / 226 | 64% | 50.50 | 259 / 406 |
tonsil | 0% | 0 | 0 / 0 | 100% | 146.60 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 74.26 | 1 / 1 |
blood vessel | 99% | 4081.25 | 1327 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 4292.56 | 1196 / 1204 | 0% | 0 | 0 / 0 |
spleen | 99% | 2777.05 | 239 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 76.54 | 77 / 80 |
heart | 95% | 2569.43 | 817 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 57% | 891.23 | 147 / 258 | 32% | 15.45 | 74 / 230 |
peripheral blood | 20% | 2530.11 | 185 / 929 | 0% | 0 | 0 / 0 |
muscle | 14% | 199.07 | 116 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 1.03 | 1 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007213 | Biological process | G protein-coupled acetylcholine receptor signaling pathway |
GO_0043547 | Biological process | positive regulation of GTPase activity |
GO_0007165 | Biological process | signal transduction |
GO_0045162 | Biological process | clustering of voltage-gated sodium channels |
GO_0007010 | Biological process | cytoskeleton organization |
GO_0007528 | Biological process | neuromuscular junction development |
GO_0043113 | Biological process | receptor clustering |
GO_0051491 | Biological process | positive regulation of filopodium assembly |
GO_0045887 | Biological process | positive regulation of synaptic assembly at neuromuscular junction |
GO_0050808 | Biological process | synapse organization |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0005796 | Cellular component | Golgi lumen |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0045202 | Cellular component | synapse |
GO_0005604 | Cellular component | basement membrane |
GO_0043202 | Cellular component | lysosomal lumen |
GO_0033691 | Molecular function | sialic acid binding |
GO_0005201 | Molecular function | extracellular matrix structural constituent |
GO_0005200 | Molecular function | structural constituent of cytoskeleton |
GO_0002162 | Molecular function | dystroglycan binding |
GO_0043236 | Molecular function | laminin binding |
GO_0043395 | Molecular function | heparan sulfate proteoglycan binding |
GO_0035374 | Molecular function | chondroitin sulfate binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | AGRN |
Protein name | Agrin Follistatin (Activin-binding protein) Agrin [Cleaved into: Agrin N-terminal 110 kDa subunit; Agrin C-terminal 110 kDa subunit; Agrin C-terminal 90 kDa fragment (C90); Agrin C-terminal 22 kDa fragment (C22)] |
Synonyms | AGRIN |
Description | FUNCTION: [Isoform 1]: Heparan sulfate basal lamina glycoprotein that plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ) and directs key events in postsynaptic differentiation. Component of the AGRN-LRP4 receptor complex that induces the phosphorylation and activation of MUSK. The activation of MUSK in myotubes induces the formation of NMJ by regulating different processes including the transcription of specific genes and the clustering of AChR in the postsynaptic membrane. Calcium ions are required for maximal AChR clustering. AGRN function in neurons is highly regulated by alternative splicing, glycan binding and proteolytic processing. Modulates calcium ion homeostasis in neurons, specifically by inducing an increase in cytoplasmic calcium ions. Functions differentially in the central nervous system (CNS) by inhibiting the alpha(3)-subtype of Na+/K+-ATPase and evoking depolarization at CNS synapses. This secreted isoform forms a bridge, after release from motor neurons, to basal lamina through binding laminin via the NtA domain.; FUNCTION: [Isoform 2]: Transmembrane form that is the predominate form in neurons of the brain, induces dendritic filopodia and synapse formation in mature hippocampal neurons in large part due to the attached glycosaminoglycan chains and the action of Rho-family GTPases.; FUNCTION: Isoform 1, isoform 4 and isoform 5: neuron-specific (z+) isoforms that contain C-terminal insertions of 8-19 AA are potent activators of AChR clustering. Isoform 5, agrin (z+8), containing the 8-AA insert, forms a receptor complex in myotubules containing the neuronal AGRN, the muscle-specific kinase MUSK and LRP4, a member of the LDL receptor family. The splicing factors, NOVA1 and NOVA2, regulate AGRN splicing and production of the 'z' isoforms.; FUNCTION: Isoform 3 and isoform 6: lack any 'z' insert, are muscle-specific and may be involved in endothelial cell differentiation.; FUNCTION: [Agrin N-terminal 110 kDa subunit]: Is involved in regulation of neurite outgrowth probably due to the presence of the glycosaminoglcan (GAG) side chains of heparan and chondroitin sulfate attached to the Ser/Thr- and Gly/Ser-rich regions. Also involved in modulation of growth factor signaling (By similarity). .; FUNCTION: [Agrin C-terminal 22 kDa fragment]: This released fragment is important for agrin signaling and to exert a maximal dendritic filopodia-inducing effect. All 'z' splice variants (z+) of this fragment also show an increase in the number of filopodia. FUNCTION: Binds directly to activin and functions as an activin antagonist. Specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH). . FUNCTION: Binds directly to activin and functions as an activin antagonist. Specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH). . |
Accessions | ENST00000652369.1 Q15952 Q96QF8 ENST00000620552.4 Q96QF9 A0A087X208 A0A494C1I6 A0A494C0G5 Q5XG79 ENST00000651234.1 ENST00000379370.7 [O00468-6] O00468 |